Metabolomic and Gut Microbial Biomarkers of Smoking Cessation Treatment in Long-term Drug Therapy: a Randomized Controlled Trial

Launched by SIGMUND FREUD PRIVATUNIVERSITAT · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of quitting smoking on individuals with substance use disorders, particularly those who struggle with alcohol and nicotine addiction. Researchers want to understand how stopping smoking can help improve emotional well-being, reduce cravings for other substances, and make it easier for people to manage their addictions. The study will last for six weeks and will compare two groups: one group will receive support to quit smoking, while the other will continue with their usual treatment. Researchers will also look at changes in participants' body chemistry and gut bacteria to see how these factors may influence addiction recovery.

To participate, individuals must be at least 18 years old, have a diagnosed substance use disorder, and be willing to quit smoking. They should also be able to understand German and provide informed consent. Participants will undergo assessments before and after the six-week intervention and will have follow-up evaluations three months later. It's important to note that some individuals, such as those with certain serious health conditions or who have recently taken specific medications, may not be eligible for this study.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: Informed consent, a diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10, minimum age of 18 years, sufficient knowledge of the German language, willingness to quit smoking.
• • -
• • Exclusion Criteria: lack of consent, age below 18, inability to provide informed consent, acute psychotic symptoms or acute suicidal tendencies, cardiovascular disease, pregnancy or breastfeeding, severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score \<20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy), probiotic intake within the last 6 months, or those consuming dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study, prior participation in a smoking cessation programme.
• • -